Company Contents
Quick Facts & Snapshot
Summary
The Biosimilar Contract Manufacturing market is entering a scale-up phase, supported by patent expiries, cost-containment policies, and expanding biologics pipelines. Leading CDMOs are consolidating share through capacity expansions, late-stage partnerships, and high-quality regulatory track records. From US$ 9.40 Billion in 2025 to US$ 24.08 Billion by 2032, the market compounds at 15.20% annually.
Source: Secondary Information and ReportMines Research Team - 2026
Ranking Methodology
The rankings of Biosimilar Contract Manufacturing market companies are derived from a composite scoring model that integrates quantitative and qualitative indicators. Core metrics include estimated 2025 biosimilar contract manufacturing revenue, active biosimilar projects, late-stage and commercial-scale manufacturing contracts, and number of facilities dedicated to biosimilars. We further assess technology differentiation such as single-use bioreactor adoption, continuous bioprocessing readiness, high-titer cell line platforms, and analytical characterization depth. Portfolio breadth across monoclonal antibodies, recombinant proteins, and complex modalities like antibody-drug conjugates is evaluated alongside geographic service coverage and regulatory track record. Finally, we score the ability to support long-term supply agreements, lifecycle management services, and digital quality systems. Scores are normalized, weighted, and peer-benchmarked to generate an overall rank, while also considering recent strategic moves, M&A, and announced capacity expansions.
Top 10 Companies in Biosimilar Contract Manufacturing
Source: Secondary Information and ReportMines Research Team - 2026
Detailed Company Profiles
Samsung Biologics
Samsung Biologics is a global CDMO leader offering massive-scale biologics and biosimilar manufacturing with integrated drug substance and drug product services.
Lonza Group
Lonza Group provides end-to-end biologics and biosimilar services, from cell line development to global commercial manufacturing for innovators and generics.
WuXi Biologics
WuXi Biologics is a fast-growing global CDMO with a single-use platform and integrated biosimilar development-to-commercialization services.
Boehringer Ingelheim BioXcellence
Boehringer Ingelheim BioXcellence delivers commercial biologics and biosimilar manufacturing with deep experience in both mammalian and microbial systems.
Fujifilm Diosynth Biotechnologies
Fujifilm Diosynth Biotechnologies is a diversified biologics CDMO excelling in microbial and mammalian biosimilar manufacturing with advanced analytics.
Catalent Biologics
Catalent Biologics specializes in biosimilar drug product, sterile fill-finish, and device-integrated solutions for injectable biologics.
Rentschler Biopharma
Rentschler Biopharma is a specialized CDMO focused on complex, mid-scale biosimilars requiring high customization and regulatory support.
AbbVie Contract Manufacturing Services
AbbVie Contract Manufacturing Services leverages internal biologics infrastructure to support select external biosimilar and biologics manufacturing programs.
Intas Biopharmaceuticals (Accord Biopharma CDMO)
Intas Biopharmaceuticals offers cost-efficient biosimilar manufacturing and global supply, leveraging strong presence in emerging and European markets.
Samsung Bioepis Contract Services
Samsung Bioepis Contract Services provides development-centric biosimilar capabilities and early-stage manufacturing, supporting technology transfer to large facilities.
SWOT Leaders
Samsung Biologics
SWOT Snapshot
Unmatched large-scale capacity, high productivity, strong regulatory record, and integrated DS-DP offerings for biosimilars.
High capital intensity and concentration in a single manufacturing hub increase operational risk exposure.
Rising global biosimilar adoption, expanded tenders, and growing outsourcing from big pharma and regional players.
Price pressure from Asian peers, potential oversupply risk, and evolving regulatory scrutiny on mega-sites.
Lonza Group
SWOT Snapshot
Diversified technology platforms, premium quality perception, and broad global manufacturing footprint across key regions.
Higher pricing relative to cost-focused CDMOs and complex organizational structure slowing decision-making.
Increasing complexity of biosimilars and demand for integrated development-to-commercialization partnerships.
Competition from agile single-use-based CDMOs and potential macroeconomic slowdowns affecting sponsor budgets.
WuXi Biologics
SWOT Snapshot
Highly flexible single-use network, competitive pricing, and strong presence across Asia, Europe, and North America.
Exposure to geopolitical tensions, export controls, and evolving international regulatory perceptions.
Globalization of Chinese biosimilar developers and increasing outsourcing by Western mid-size companies.
Trade restrictions, data security concerns, and local capacity build-out by sponsors in key markets.
Biosimilar Contract Manufacturing Market Regional Competitive Landscape
North America remains the most lucrative demand center for Biosimilar Contract Manufacturing market companies, driven by large biologics spend, patent expiries, and payer pressure for cost savings. Catalent Biologics, Lonza, and Samsung Biologics increasingly compete for late-stage and commercial contracts, while US-based biotechs outsource development and fill-finish to manage capital constraints.
Europe is a mature, highly regulated biosimilar market with strong tender mechanisms that favor capable, efficient Biosimilar Contract Manufacturing market companies. Lonza Group, Boehringer Ingelheim BioXcellence, Fujifilm Diosynth Biotechnologies, and Rentschler Biopharma play pivotal roles, supported by dense hospital networks and aggressive payer policies incentivizing biosimilar uptake.
Asia-Pacific is the fastest-growing supply hub, anchored by Samsung Biologics, WuXi Biologics, Intas Biopharmaceuticals, and Samsung Bioepis Contract Services. Governments in South Korea, China, and India promote domestic biomanufacturing capabilities, while global sponsors leverage regional CDMOs for cost advantage, scalable capacity, and strategic access to growing local patient populations.
Latin America is emerging as a significant volume opportunity for cost-competitive Biosimilar Contract Manufacturing market companies, particularly Intas Biopharmaceuticals and regional partners aligned with global CDMOs. Policy frameworks in Brazil, Mexico, and Argentina increasingly recognize biosimilars, creating demand for localized packaging, labeling, and technology-transfer from established manufacturing hubs.
The Middle East and Africa region is still nascent but strategically important, with governments seeking to localize biopharmaceutical manufacturing capabilities. Biosimilar Contract Manufacturing market companies are exploring joint ventures and technology-transfer arrangements, especially for oncology and autoimmune biosimilars, to improve access and mitigate reliance on imported originator biologics.
Central and Eastern Europe, including Poland and Czech Republic, is attracting investment from Biosimilar Contract Manufacturing market companies seeking lower-cost yet EU-compliant manufacturing bases. These facilities often serve as bridging hubs, supplying both Western Europe and neighboring emerging markets under harmonized regulatory frameworks.
Biosimilar Contract Manufacturing Market Emerging Challengers & Disruptive Start-Ups
Emerging Challengers & Disruptive Start-Ups
Single-use, fully modular biosimilar manufacturing platform enabling rapid scale-out and flexible multi-product campaigns for regional and global sponsors.
Cloud-native, AI-driven manufacturing execution system tailored for Biosimilar Contract Manufacturing market companies to optimize yields and reduce batch failures.
Low-cost biosimilar CDMO focused on emerging market tenders, leveraging highly automated facilities and optimized process intensification strategies.
Mid-scale European CDMO offering continuous bioprocessing solutions, targeting complex biosimilars and accelerated tech-transfer from discovery-stage sponsors.
Regional biosimilar manufacturer creating near-shore capabilities for Latin America, combining localized fill-finish with partnerships for imported drug substance.
Biosimilar Contract Manufacturing Market Future Outlook & Key Success Factors (2026-2032)
From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Biosimilar Contract Manufacturing market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.
Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Biosimilar Contract Manufacturingmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.
Frequently Asked Questions
Find answers to common questions about this company report.